奥锐特药业股份有限公司 关于通过药品GMP符合性检查的公告

Group 1 - The company, Aorite Pharmaceutical Co., Ltd., has received a GMP compliance inspection notice from the Zhejiang Provincial Drug Administration, confirming that its production lines meet the required standards [1] - The inspection covered the production of active pharmaceutical ingredients, specifically mometasone furoate and betamethasone, conducted from November 12 to November 14, 2025 [1] - The inspection concluded that the company complies with the relevant laws and regulations, including the Drug Administration Law and the Good Manufacturing Practice (GMP) guidelines [1] Group 2 - The company is expected to maintain stable product quality and production capacity, which will help meet market demand for its pharmaceutical products [3] - The company acknowledges that future sales may be influenced by market conditions and industry policies, indicating potential uncertainties in the pharmaceutical sector [3]